Summary
Differentials
Common
- Hamartoma
- Infectious
- Primary lung cancer
- Metastatic cancer
- Intrapulmonary lymph node
- Sarcoidosis
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (formerly known as Wegener granulomatosis)
Uncommon
- Carcinoid tumor
- Lymphoma
- Arteriovenous malformation
- Pulmonary amyloidosis
- Mucoid impaction
Contributors
Authors
Dr George Tsaknis, MD, PhD, FRCP(London), MRQA, MAcadMEd, PGCert
Honorary Senior Lecturer
Department of Respiratory Sciences
University of Leicester
Leicester
UK
Consultant in Respiratory Medicine and Lung Cancer Lead
Clinical Director
Lung Cancer Screening Programme
Kettering General Hospital
Kettering
UK
Disclosures
GT declares that he has no competing interests.
Dr Harvinder Virk, MBChB (Hons), MA (Oxon), MRes, PhD, MRCP
NIHR Academic Clinical Lecturer in Respiratory Medicine
Department of Respiratory Sciences
University of Leicester
Leicester
UK
Disclosures
HV declares that he has no competing interests.
Acknowledgements
Dr George Tsaknis and Dr Harvinder Virk would like to gratefully acknowledge Dr Peter J. Mazzone and Dr Erik E. Folch MD, previous contributors to this topic.
Disclosures
PJM has been paid to participate in clinical advisory board meetings for Oncimmune, InDi, Nucleix, Grail, and Oncocyte, all companies interested in developing molecular biomarkers for the evaluation of lung nodules/lung cancer; he does not have a contractual agreement to disseminate product information for any of these companies. PJM has participated in research supported by InDi Veracyte, funding for which was paid to his institution. He has also participated in research with in-kind support from Oncimmune and 20/20 Genesystems. EEF is the global principal investigator for the NAVIGATE trial, sponsored by Medtronic. He has also served as scientific consultant for Boston Scientific in the development of advanced bronchoscopic techniques.
Peer reviewers
Pallav L. Shah, MD, MBBS, FRCP
Consultant Physician
Royal Brompton Hospital
Chelsea & Westminster Hospital
London
UK
Disclosures
PLS declares that he has no competing interests.
Sangeeta M. Bhorade, MD
Associate Professor of Medicine
Medical Director
Lung Transplant Program
University of Chicago Hospitals
Chicago
IL
Disclosures
SMB declares that she has no competing interests.
References
Key articles
American College of Radiology. ACR appropriateness criteria: incidentally detected indeterminate pulmonary nodule. 2023 [internet publication].Full text
Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015 Aug;70 Suppl 2:ii1-54.Full text Abstract
MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017 Jul;284(1):228-43.Full text Abstract
Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e93S-120.Full text Abstract
Ruparel M, Quaife SL, Navani N, et al. Pulmonary nodules and CT screening: the past, present and future. Thorax. 2016 Apr;71(4):367-75.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Patient information
Lung cancer (non-small-cell)
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer